KRAS G12D
Clinical trials for KRAS G12D explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D trials appear
Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…
Matched conditions: KRAS G12D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New immune cell therapy targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called RE002 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The treatment uses specially designed immune cells (T cells) to attack the cancer. About 30 adults whose cancer has not responded to st…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with abnormal blood vessels (vascular malformations). One drug, alpelisib, is for slow-flow types; the other, mirdametinib, is for fast-flow types. About 50 participants aged 2 and older will take the drug for 48 weeks to see if thei…
Matched conditions: KRAS G12D
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …
Matched conditions: KRAS G12D
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
First-in-Human trial launches 'Living Drug' to hunt deadly cancer mutations
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack can…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC